[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100382323":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":28,"studyPopulation":21,"armGroups":29,"interventions":47,"overallOfficials":21,"centralContacts":53,"locations":63,"responsibleParty":145,"collaborators":21,"id":147,"slug":21,"hasResults":148,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":148,"sex":154,"minAge":155,"maxAge":21,"enrollmentInfo":156,"targetDuration":21,"studyType":159,"phases":160,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":66,"whyStopped":21,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":180},{"fullName":5,"class":6},"Institut Bergonié","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":21},[9],{"measure":10,"description":11,"timeFrame":12},"Assessment of cancer outcome in terms of overall survival (2 distincts population)","Overall Survival (OS) is defined as the time interval between the date of randomization and the date of death (of any cause).","18 months",[14,18],{"measure":15,"description":16,"timeFrame":17},"Proportion of patients with at least one actionable alteration (in 2 distincts populations)","An actionable alteration is determined according to the molecular tumor board.","Throughout the study: an average of 18 months",{"measure":19,"description":20,"timeFrame":17},"Proportion of patients treated with a targeted therapy (in 2 distincts populations)","A profiling-based targeted therapy corresponds to a therapy targeting an actionable alteration",null,{"allocation":23,"interventionModel":24,"interventionModelDescription":25,"primaryPurpose":6,"observationalModel":21,"timePerspective":21,"maskingInfo":26},"RANDOMIZED","PARALLEL","For each distinct population of patients with Advanced solid tumor (colorectal cancer and non-small-cell lung cancer), patients will be randomized between two arms:\n\nExperimental procedure: initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis (subsequent MTBs at each radiological assessment).\n\nStandard procedure: initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging.",{"masking":27,"maskingDescription":21,"whoMasked":21},"NONE","Primary tumor tissue, if accessible at all, does not always provide enough information to stratify individual patients to the most promising therapy. Re-analysis of metastatic lesions by needle biopsy is possible but invasive, and limited by the known intra-patient heterogeneity of individual lesions. These hurdles might be overcome by analyzing circulating tumor DNA (liquid biopsy), which in principle might reflect all subclones present at that specific time point and allow sequential monitoring of disease evolution.\n\nOnce tumor's genetic profiling is available, patients will be discussed within a multidisciplinary tumor board (MTB) which aims at discussing the genomic profiles and at providing a therapeutic decision for each patient. This MTB involves clinical oncologists, molecular biologists and clinical or biological project manager.\n\nAll the patients carrying an actionnable alteration will be proposed to receive a matched drug or to enter in a matched clinical trial depending on the possibility of inclusion at the time of molecular report.\n\nthe investigators hypothesize that implementing sequential circulating tumor DNA analysis can improve management of patients with advanced cancer and therefore their survival.",[30,36,40,44],{"label":31,"type":32,"description":33,"interventionNames":34},"Experimental procedure for colorectal cancer","EXPERIMENTAL","Patients with Advanced colorectal cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis (subsequent MTBs at each radiological assessment)",[35],"Genetic: Liquid biopsy",{"label":37,"type":38,"description":39,"interventionNames":21},"Standard procedure for colorectal cancer","NO_INTERVENTION","Patients with Advanced colorectal cancer will be managedby initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging.",{"label":41,"type":32,"description":42,"interventionNames":43},"Experimental procedure for non-small cell lung cancer","Patients with Advanced non-small cell lung cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis (subsequent MTBs at each radiological assessment)",[35],{"label":45,"type":38,"description":46,"interventionNames":21},"Standard procedure for non-small cell lung cancer","Patients with Advanced non-small cell lung cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging.",[48],{"type":49,"name":50,"description":51,"armGroupLabels":52,"otherNames":21},"GENETIC","Liquid biopsy","Liquid biopsy will be performed at cycle 1 day 1 and cycle 2 day of each line of systemic treatment, at each tumor evaluation by Imaging and at confirmation of progression",[31,41],[54,60],{"name":55,"role":56,"phone":57,"phoneExt":58,"email":59},"Antoine ITALIANO, MD, PhD","CONTACT","5.56.33.33.33","+33","a.italiano@bordeaux.unicancer.fr",{"name":61,"role":56,"phone":21,"phoneExt":21,"email":62},"Simone MATHOULIN-PELISSIER, MD, PhD","s.mathoulin@bordeaux.unicancer.fr",[64,82,96,106,117,131],{"facility":65,"status":66,"city":67,"state":21,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"Centre hospitalier de la Côte Basque","RECRUITING","Bayonne","64109","France","FR",{"type":72,"coordinates":73},"Point",[74,75],-1.473,43.49316,{"lat":75,"lon":74},[78,80],{"name":79,"role":56,"phone":21,"phoneExt":21,"email":21},"Thomas GRELLETY, MD",{"name":21,"role":56,"phone":21,"phoneExt":21,"email":81},"tgrellety@ch-cotebasque.fr",{"facility":83,"status":66,"city":84,"state":21,"zip":85,"country":69,"countryCode":70,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Clinique Tivoli-Ducos","Bordeaux","33000",{"type":72,"coordinates":87},[88,89],-0.58046,44.84124,{"lat":89,"lon":88},[92,94],{"name":93,"role":56,"phone":21,"phoneExt":21,"email":21},"Valérie COCHIN, MD",{"name":21,"role":56,"phone":21,"phoneExt":21,"email":95},"v.cochin@tivoli-oncologie.fr",{"facility":97,"status":66,"city":84,"state":21,"zip":98,"country":69,"countryCode":70,"cosmosGeoPoint":99,"geoPoint":101,"contacts":102},"Institut Bergonie","33076",{"type":72,"coordinates":100},[88,89],{"lat":89,"lon":88},[103,104],{"name":55,"role":56,"phone":21,"phoneExt":21,"email":59},{"name":55,"role":105,"phone":21,"phoneExt":21,"email":21},"PRINCIPAL_INVESTIGATOR",{"facility":107,"status":66,"city":84,"state":21,"zip":108,"country":69,"countryCode":70,"cosmosGeoPoint":109,"geoPoint":111,"contacts":112},"Polyclinique Bordeaux Nord Aquitaine","33077",{"type":72,"coordinates":110},[88,89],{"lat":89,"lon":88},[113,115],{"name":114,"role":56,"phone":21,"phoneExt":21,"email":21},"Cédric LECAILLE, MD",{"name":21,"role":56,"phone":21,"phoneExt":21,"email":116},"lecail@hotmail.fr",{"facility":118,"status":66,"city":119,"state":21,"zip":120,"country":69,"countryCode":70,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"CHRU Brest","Brest","29200",{"type":72,"coordinates":122},[123,124],-4.48628,48.39029,{"lat":124,"lon":123},[127,129],{"name":128,"role":56,"phone":21,"phoneExt":21,"email":21},"Jean-Philippe METGES, MD,PhD",{"name":21,"role":56,"phone":21,"phoneExt":21,"email":130},"jean-philippe.metges@chu-brest.fr",{"facility":132,"status":66,"city":133,"state":21,"zip":134,"country":69,"countryCode":70,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Polyclinique Marzet","Pau","64000",{"type":72,"coordinates":136},[137,138],-0.35583,43.31117,{"lat":138,"lon":137},[141,143],{"name":142,"role":56,"phone":21,"phoneExt":21,"email":21},"Sylvestre LE MOULEC, MD",{"name":21,"role":56,"phone":21,"phoneExt":21,"email":144},"sylvestre.lemoulec@gmail.com",{"type":146,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100382323",false,"NCT04258137","Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study","Circulating DNA to Improve Outcome of Oncology PatiEnt: A Randomized Study - COPE Study","COPE","Inclusion Criteria:\n\n1. Age ≥ 18 years,\n2. Histology: colorectal cancer, non-small cell lung cancer,\n3. Locally advanced\u002Funresectable and\u002For metastatic solid tumor,\n4. Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C 2 (Appendix 1),\n5. Measurable disease according to RECIST 1.1 (lesion in previously irradiated filed can be considered as measurable if progressive at inclusion according to RECIST v1.1). At least one site of disease must be uni-dimensionally \\> 10 mm,\n6. No previous systemic treatment for advanced disease,\n7. Availability of suitable paraffin embedded (FFPE) archive tumor material or at least one target lesion that can be biopsied for research purpose,\n8. Eligible to first-line systemic therapy,\n9. Patient with a social security in compliance with the French law,\n10. Voluntary signed and dated written informed consent prior to any study specific procedure.\n\nExclusion Criteria:\n\n1. Inability to swallow,\n2. Major problem with intestinal absorption,\n3. Previous allogeneic bone marrow transplant,\n4. Previous or current malignancies of other histologies within the last 2 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin and prostate cancer,\n5. Evidence of severe or uncontrolled systemic disease (uncontrolled hypertension, active bleeding diatheses, or active Hepatitis B, C and HIV),\n6. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol,\n7. Individuals deprived of liberty or placed under guardianship,\n8. Pregnant or breast feeding women,\n9. Previous enrolment in the present study,\n10. Any contraindication to first-line systemic therapy.","ALL","18 Years",{"count":157,"type":158},332,"ESTIMATED","INTERVENTIONAL",[161],"NA","COPE is a biology driven protocol with 2 independent, multicentric, two-arm non-comparative randomized (2:1) phase II trials in 2 distinct populations: colorectal cancer patients and non-small-lung cancer patients.\n\nFor each phase II trial, patient will be randomized between two arms with two patients randomized in arm A for one patient randomized in arm B:\n\n* Arm A (Experimental - initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis)\n* Arm B (Standard - initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging).",[164,165],"Colorectal Cancer","Non Small Cell Lung Cancer",[167,168,169,170],"advanced","metastatic","liquid biopsy","genetic profiling","2025-10-01",{"date":173,"type":174},"2025-10-02","ACTUAL",{"date":176,"type":174},"2020-09-04",{"date":178,"type":158},"2027-12-01",{"name":5,"class":6},6]